Neurodevelopment and quality of life for children with hypoplastic left heart syndrome: current knowns and unknowns

Caren S Goldberg1, Kathleen Mussatto, Daniel Licht

  • 1Pediatric Cardiology, C. S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI 48109, USA. cgoldber@umich.edu

Cardiology in the Young
|December 14, 2011
PubMed

Insights

This review covers neurodevelopmental outcomes and quality of life for children with hypoplastic left heart syndrome (HLHS). It highlights current knowledge and identifies future research directions for HLHS care.

Area of Science:

  • Pediatric Cardiology
  • Neurodevelopmental Pediatrics
  • Congenital Heart Disease Research

Background:

  • Hypoplastic left heart syndrome (HLHS) is a complex congenital heart defect requiring significant medical intervention.
  • Long-term survival has improved, necessitating a focus on developmental trajectories and quality of life.
  • Understanding the multifaceted challenges faced by HLHS survivors is crucial for comprehensive care.

Purpose of the Study:

  • To synthesize current knowledge on neurodevelopmental outcomes in pediatric HLHS patients.
  • To evaluate the quality of life experienced by children with HLHS.
  • To identify critical knowledge gaps and propose future research avenues for HLHS.

Main Methods:

  • Systematic literature review of studies focusing on neurodevelopment and quality of life in HLHS.
  • Analysis of existing data on cognitive, motor, and socio-emotional development.
  • Qualitative and quantitative assessment of patient-reported and caregiver-reported quality of life measures.

Main Results:

  • Neurodevelopmental challenges, including cognitive and motor delays, are prevalent in HLHS survivors.
  • Quality of life is variable, influenced by medical complexity, developmental status, and psychosocial factors.
  • Significant heterogeneity exists in outcomes, underscoring the need for individualized assessments.

Conclusions:

  • Current literature provides a foundation for understanding HLHS neurodevelopmental outcomes and quality of life.
  • Further research is essential to elucidate specific risk factors and effective interventions.
  • Longitudinal studies are needed to track development and optimize lifelong care for HLHS patients.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...